Cardiff Oncology Inc (CRDF)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Mark Erlander
Employees:
20
11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
858-952-7570
Date | Ratio |
---|---|
2004-07-27 | 111:1 |
2012-05-30 | 1:6 |
2018-06-04 | 1:12 |
2019-02-20 | 1:6 |
Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|